LNSR News and Press, LENSAR Inc. From 02/26/24

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s fourth quarter and full year 2023 financial results wi...

2023-11-11 12:32:09 ET LENSAR, Inc. (LNSR) Q3 2023 Earnings Conference Call November 9, 2023 8:30 AM ET Company Participants Cameron Radinovic - Burns McClellan Nicholas Curtis - CEO Thomas Staab - CFO Conference Call Participants Ryan Zimmerman - BTI...

2023-11-09 12:48:45 ET More on LENSAR LENSAR, Inc. (LNSR) Q2 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on LENSAR Historical earnings data for LENSAR Financial information for LENSAR For further details see: LENSAR GAAP EPS ...

Increased ALLY ® Adaptive Cataract Treatment System installed base to 39 systems with a backlog of 8 additional systems for installation as of September 30, 2023 Total revenue increased 26% and U.S. procedure volume increased 16% over the third quarter 2022 LENSAR, Inc....

Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...

LENSAR, Inc. (Nasdaq: LNSR) (“LENSAR” or “the Company”), a global medical technology company focused on advanced femtosecond laser solutions for the treatment of cataracts, today announced that the Company’s third quarter 2023 financial results will be released ...

2023-08-11 18:04:10 ET LENSAR, Inc. (LNSR) Q2 2023 Earnings Conference Call August 09, 2023 8:30 AM ET Company Participants Cameron Radinovic – Burns McClellan Nick Curtis – Chief Executive Officer Tom Staab – Chief Financial Officer Co...

2023-08-09 07:20:21 ET LENSAR press release ( NASDAQ: LNSR ): Q2 GAAP EPS of -$0.81 misses by $0.46 . Revenue of $12.01M (+49.4% Y/Y) beats by $2.01M . Increased ALLY ® Adaptive Cataract Treatment System installed base to 28 systems with a backlog of 6...

Increased ALLY ® Adaptive Cataract Treatment System installed base to 28 systems with a backlog of 6 additional systems for installation as of June 30, 2023 U.S. procedure volumes increased 13% over second quarter 2022; 1H 2023 procedure volumes increased 15% year-over-year at si...

Private equity-owned ophthalmology group, EyeSouth Partners, adopts ALLY for each operating room within its Gainesville, Georgia and Boynton Beach, Florida Ambulatory Surgery Centers (ASCs) Private equity-owned ophthalmology groups account for 14% of the U.S. based ASCs performing catarac...